FLT3 and acute myeloid leukemia: Reducing the risk of relapse after allogeneic stem cell transplantation by maintenance therapy with non‐cytotoxic drugs is an active field of research going beyond FLT3 inhibitors, and virtually all the small molecules inhibitors having shown efficacy in AML will be assessed in this context [89, 90].